| アブストラクト | PURPOSE OF REVIEW: To provide a better understanding of the risk of anaphylaxis due to antiallergic and antiasthmatic biologics through an analysis of data reported in literature and in clinical trials, and by conducting a retrospective descriptive analysis of individual case safety reports on VigiBase, the WHO International Pharmacovigilance database. RECENT FINDINGS: Analysis of the data, as described, demonstrated safety of the antiallergic and antiasthmatic biologics with a low incidence of anaphylaxis. SUMMARY: Biologic therapies have revolutionized the treatment of many diseases, such as atopic dermatitis, nasal polyps, spontaneous chronic urticarial and severe asthma with a precise immunological action, in the sphere of precision medicine.Albeit these drugs are generally well tolerated, generating real-world evidence is crucial to re-evaluate clinically relevant adverse events, such as anaphylaxis, allowing to confirm their safety profile in particular in special populations such as paediatric patients. |
|---|
| ジャーナル名 | Current opinion in allergy and clinical immunology |
|---|
| Pubmed追加日 | 2023/8/9 |
|---|
| 投稿者 | Furci, Fabiana; Luxi, Nicoletta; Senna, Gianenrico; Trifiro, Gianluca |
|---|
| 組織名 | Provincial Healthcare Unit, Section of Allergy, Vibo Valentia.;Department of Medicine, University of Verona.;Allergy Unit and Asthma Center, Verona University Hospital.;Department of Diagnostics and Public Health, Section of Pharmacology, University;of Verona, Verona, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37555938/ |
|---|
